Alector Hands Genentech Its Parkinson's Enzyme Drug For $100 Million Upfront, With Up To $1.17 Billion More Possible
The company says the deal lifts pro forma cash to about $223.7 million, enough to fund operations into 2029.
Alector will receive a $100 million upfront payment from Genentech for exclusive worldwide rights to AL050, its brain-penetrant Parkinson's enzyme therapy, according to an 8-K filed Monday. Up to $1.17 billion in milestone payments could follow, and Alector keeps the blood-brain barrier platform behind the drug.
What the 8-K says
Alector and Genentech signed the license on September 30, with the disclosure coming Monday. Genentech takes over development, regulatory work, manufacturing and commercialization of AL050 across all indications, and Alector will assign it certain patents specific to the drug.
Beyond the $100 million, the milestones are tied to development, regulatory and commercial targets. Alector is also eligible for tiered royalties on net sales, at rates running from single-digit to double-digit percentages.
Genentech may end the deal for convenience on written notice. Either side can terminate for insolvency or an uncured material breach. On certain terminations, Genentech would return some patents and assets to Alector. For a set period, Alector also faces restrictions on certain compounds and products that contain or target GCase, the enzyme involved.
Alector says it will file the agreement as an exhibit to a later periodic report, with confidential portions redacted.
What Alector keeps, and what it owes Spur
Alector retains its Alector Brain Carrier platform and full rights to use it across its wholly owned pipeline outside GCase. CEO Arnon Rosenthal said the cash runway extends into 2029 and will fund an Alzheimer's antibody toward multi-cohort clinical data, plus tau and alpha-synuclein siRNA programs through IND-enabling studies and IND filings.
A second agreement carries a cost. On September 30, Alector exercised its option to license engineered GCase patents from Spur Therapeutics under an August 14, 2026 agreement, having paid $500,000 upfront for the option. It now owes Spur $15 million, plus a percentage in the teens of milestone and other non-royalty partnering income, including Genentech milestones. Spur also gets a share of royalties Alector receives.
The cash picture
Preliminary, unaudited cash, cash equivalents and marketable securities were about $138.7 million at September 30. After the initial Genentech payment and the Spur payment, Alector says that would be about $223.7 million, which it believes funds operations into 2029.
The quarter-end close is not complete, and the auditor has performed no procedures on the figure. Shares closed at $1.81 at Friday's close, down 2.69% (market data), before the Monday disclosure.
What to watch
Alector will host a scientific webinar on Tuesday, October 13, at 8:00 a.m. PT on its Alzheimer's antibody and its tau and alpha-synuclein siRNA programs.
The final cash figure arrives only when Alector completes its September 30 quarter-end close.
Sources
- 8-K Filing — Alector, Inc. (ALEC) — SEC EDGAR
- Exhibit alec-ex99_01.htm — Alector, Inc. 8-K exhibit — SEC EDGAR
